

# Understanding Allogeneic HCT Trends and Diversity

## WHAT?

- Study analyzing real-world data on allogeneic hematopoietic cell transplantation (HCT) in the U.S.
- Focus on practice trends, donor types, graft-versus-host disease (GVHD) prophylaxis, and patient outcomes.
- Examination of how ethnically diverse patients access allogeneic HCT.

## WHY?

- Investigate shifts in allogeneic HCT practices and outcomes.
- Address challenges faced by ethnically diverse patients in accessing suitable donors.
- Explore the impact of novel GVHD prophylaxis.

## WHEN?

- Data collected over multiple years, including analysis of recent trends.
- Study conducted in the context of the COVID-19 pandemic's influence on medical practices.

## WHO?

Patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR).



# RESULTS

- Total allogeneic HCTs decreased in 2020, reflecting pandemic-related challenges.
- Increased use of alternative donor platforms, like haploidentical donors and mismatched unrelated donors observed in recent years.
- Positive impact of post-transplant cyclophosphamide (PTCy) as GVHD prophylaxis.
- Ethnically diverse patients benefited from alternative donor strategies and improved survival rates.
- Racial and ethnic disparities persist, prompting the need for holistic solutions.

Read the CIBMTR Outcomes & Trends study results in Transplantation and Cellular Therapy (DOI: [10.1016/j.jtct.2023.03.007](https://doi.org/10.1016/j.jtct.2023.03.007))

# IMPACT

- Emphasizes the importance of PTCy-based GVHD prophylaxis in expanding access to diverse patient populations.
- Urges addressing access barriers faced by ethnically diverse patients.
- Promotes better data collection and real-world evidence utilization.
- Calls for diversity and inclusion in clinical trials and addressing underlying health disparities.
- Call to action for the field to continue to enhance alternative donor platforms.

# FROM THE EXPERTS

*"HLA diversity associated with ethnic diversity was once an insurmountable barrier to allogeneic hematopoietic transplantation. However, use of alternative donor types and post-transplant cyclophosphamide to prevent graft-versus-host disease has enabled more ethnically diverse patients to receive this potentially life-saving therapy. As a result, ethnically diverse patients now have hope of disease cure. We have much to do to address non-HLA barriers to transplant for patients in need. But finding a donor for all patients in need seems to be a realization once considered unachievable."*

**Jeffery Auletta, MD**

Senior Vice President, Patient Outcomes and Experience, NMDP/Be The Match®  
Chief Scientific Director, CIBMTR®

